Case Report: BKV-specific T cells: a fast, safe and potentially effective treatment option for refractory BKV infections in pediatric patients after allogeneic stem cell transplantation - Top-Institutions - MDSpire

Case Report: BKV-specific T cells: a fast, safe and potentially effective treatment option for refractory BKV infections in pediatric patients after allogeneic stem cell transplantation

  • By

  • Sven Oberwegner

  • Steffen A. Hettler

  • Luca Hensen

  • Amadeus T. Heinz

  • Christiane Braun

  • Michaela Döring

  • Peter Lang

  • May 7, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Leiden University
    Leiden University

    Leiden, South Holland

    Key Differentiators

    • Pediatric Hematology-Oncology

  • #2

    University of Pavia
    University of Pavia

    Pavia, Lombardy

    Key Differentiators

    • Pediatric Hematology-Oncology

  • #3

    University of Freiburg
    University of Freiburg

    Freiburg, Baden-Württemberg

    Key Differentiators

    • Pediatric Hematology-Oncology

  • #4

    University of Tübingen
    University of Tübingen

    Tübingen, Baden-Württemberg

    Key Differentiators

    • Pediatric Hematology-Oncology

  • #5

    University of Perugia
    University of Perugia

    Perugia, Umbria

    Key Differentiators

    • Pediatric Hematology-Oncology

Original Source(s)

Case Report: BKV-specific T cells: a fast, safe and potentially effective treatment option for refractory BKV infections in pediatric patients after allogeneic stem cell transplantation

  • by Sven Oberwegner, Steffen A. Hettler, Luca Hensen, Amadeus T. Heinz, Christiane Braun, Michaela Döring, Peter Lang

  • May 7, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...